Importantly, single-cell transcriptomic analyses have revealed that in certain malignancies, KOR constitutes the predominant—or even exclusive—opioid receptor subtype expressed within the tumor microenvironment (Montagna et al., 2021), providing a compelling rationale for its exploitation as a precision oncologic target. Here, OPRK1 is linked to neoplasm.